Tests Lenti-HPV-07 vaccine against HPV-linked cervical or throat cancer
Tests Lenti-HPV-07, a new HPV-targeting treatment, in adults with HPV-linked cervical or oropharyngeal cancer.
Plain-language title generated from the registry record
Registry title: A Study to Evaluate Lenti-HPV-07 Immunotherapy Against HPV+ Cervical or Oropharyngeal Cancer
Key facts
- Where
- Orlando, Tampa, and Tulsa, United StatesSee the 4 sites
- Phase
- Phase 1/2
Where in United States
- Florida Cancer Specialists (from Sarah Canon research Institute)Orlando, United StatesTaking people
- Moffitt Cancer CenterTampa, United StatesTaking people
- Tampa General HospitalTampa, United StatesTaking people
- Oklahoma Cancer Specialists and Research Institute, LLCTulsa, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Theravectys S.A.
- Trial code
- NCT06319963
- Record updated
- 10 November 2026
- Original description
The goal of this clinical trial is to learn about the safety and efficacy of a potential new treatment called Lenti-HPV-07 in patients with a cancer induced by Human Papilloma Virus (HPV).Read full original descriptionShow less
An Open-Label Phase 1/2a Clinical Trial to Evaluate the Safety, Immunogenicity, and Preliminary Efficacy of a Lentiviral Vector-Based Therapeutic Vaccine Against Human Papilloma Virus (Lenti-HPV-07) in Participants With HPV-Associated Oropharyngeal Squamous Cell Cancer or Cervical Cancer
The goal of this clinical trial is to learn about the safety and efficacy of a potential new treatment called Lenti-HPV-07 in patients with a cancer induced by Human Papilloma Virus (HPV).
The main questions aim to answer are:
* Is Lenti-HPV-07 safe? * Does Lenti-HPV-07 induce an immune response?
Participants will be assigned to a group based on their cancer type
* either study drug group A: recurrent and/or metastatic cancer * or study drug group B: newly diagnosed with locally advanced cancer
After they finish the study treatment, they will be followed for up to 1 year. Follow-up visits will occur via clinic visits or phone calls 4 weeks after the last study treatment and then quarterly for up to 1 year.
Inclusion: histologically confirmed invasive HPV-related oropharyngeal or cervical cancer; ECOG performance status of 0 or 1; adequate hepatic, renal, pulmonary, and bone marrow/hematological function.
Exclusion: with seropositivity for HIV, active hepatitis C virus (HCV) infection, or hepatitis B (HBV) infection.